KAI Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a second Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C... [more]

View complete Press Release article